COSCIENS BIOPHARMA INC (CSCI) Stock Income Statement
NASDAQ:CSCI - Nasdaq - CA22112H1010 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 9.03M | 9.59M | 7.14M | 5.60M | 5.30M | |||
| Cost Of Goods | 4.76M | 4.86M | 4.21M | 200.00K | 100.00K | |||
| Gross Profit | 4.27M | 4.73M | 2.94M | 5.50M | 5.20M | |||
| Operating Expenses | 20.08M | 18.75M | 7.57M | 20.60M | 13.80M | |||
| Research and Development | 8.37M | 8.30M | 2.04M | 12.50M | 6.60M | |||
| Selling, General, and Administrative Expenses | 11.58M | 10.45M | 5.53M | 8.20M | 5.90M | |||
| Operating Income | -15.82M | -14.02M | -4.63M | -15.20M | -8.70M | |||
| Interest Income/Expense | 381.00K | 360.00K | -101.00K | 900.00K | 200.00K | |||
| Other Income/Expense | 2.63M | 2.69M | 360.00K | 0.00 | 0.00 | |||
| Non Recurring Items | N/A | -4.26M | 0.00 | -8.40M | 0.00 | |||
| Income Before Taxes | -17.07M | -15.22M | -4.37M | -22.70M | -8.50M | |||
| Income Tax | 496.00K | 84.00K | -885.00K | 0.00 | -100.00K | |||
| Net Income | -17.56M | -15.31M | -3.48M | -22.70M | -8.40M | |||
| EBITDA | -13.93M | -12.42M | -3.19M | -15.06M | -8.55M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -5.80 | -5.93 | -1.89 | -4.63 | -1.82 | |||
| Non GAAP EPS | N/A | N/A | -11.00 | -2.94 | N/A | |||
| Statistics | ||||||||
| Gross Profit Margin | 47.26% | 49.33% | 41.13% | 98.21% | 98.11% | |||
| Profit Margin | -194.50% | -159.68% | -48.79% | -405.36% | -158.49% | |||
| Operating Profit Margin | -175.15% | -146.27% | -64.80% | -271.43% | -164.15% | |||
All data in USD